SCHEMBL4914698

SCHEMBL4914698

Cc1nc(Nc2cccc3ccccc23)sc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
MAPT P10636 10/20 0.53
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 5/20 0.53
HTT P42858 2/20 0.53
NPC1 O15118 6/20 0.52
NPSR1 Q6W5P4 2/20 0.52
RAB9A P51151 6/20 0.51
POLB P06746 3/20 0.51
HPGD P15428 2/20 0.51
CCR4 P51679 1/20 0.51
MEN1 O00255 4/20 0.51
GAA P10253 2/20 0.51
CASP3 P42574 1/20 0.50
SENP8 Q96LD8 1/20 0.50
SENP7 Q9BQF6 1/20 0.50
SENP6 Q9GZR1 1/20 0.50
TDP1 Q9NUW8 1/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923629 0.85 MAPT (0.56) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL4914801 0.83 MAPT (0.53) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL27957021 0.82 MAPT (0.54) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL4914715 0.81 ALDH1A1 (0.48) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL4924626 0.80 MAPT (0.76) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL4765972 0.80 NPC1 (0.76) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL4196428 0.79 SMN1; SMN2 (0.81) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL347317 0.78 SMN1; SMN2 (0.52) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL347316 0.78 SMN1; SMN2 (0.52) KMT2ASMN1; SMN2MAPTALDH1A1KDM4E
SCHEMBL4484139 0.75 CDK5 (0.72) KMT2ASMN1; SMN2MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US claimed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US disclosed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US disclosed
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family DEVGEN NV (BE) 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125432-A1 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family KCNA5, KCNA1, KCNJ2 KMT2A 1740/4885SMN1; SMN2 2251/4885MAPT 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.